Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Spero Therapeutics Inc. | SPR206 | Multi-drug resistant (MDR) Gram-negative bacterial infections (renal impairment trial) | Phase 2 | Trial Discontinued | Intravenous | Antibiotic |
| Spero Therapeutics Inc. | SPR206 - (BAL) | MDR Gram-negative bacterial infections | Phase 2 | Trial Discontinued | Intravenous | Antibiotic |
| Spero Therapeutics Inc. | SPR720 | Nontuberculous mycobacterial (NTM) pulmonary disease (PD) | Phase 2a | Trial Discontinued | oral | Respiratory |
| Spero Therapeutics Inc. | SPR720 | Nontuberculous mycobacterial (NTM) pulmonary disease (PD) | Phase 2a | Trial Discontinued | oral | Respiratory |
| SpringWorks Therapeutics Inc. | OGSIVEO (nirogacestat) | Ovarian Granulosa Cell Tumors | Phase 2 | Ongoing | oral | Oncology |
| SpringWorks Therapeutics Inc. | Nirogacestat | Desmoid tumors - children (Children’s Oncology Group) | Phase 2 | Ongoing | Oral | Oncology |
| Spruce Biosciences Inc. | Tralesinidase alfa enzyme replacement therapy (TA-ERT) | Sanfilippo Syndrome Type B (MPS IIIB) | BLA Filing | Ongoing | Intravenous | Genetic Disorder |
| Spruce Biosciences Inc. | Tildacerfont - (CAHmelia-204) | Congenital Adrenal Hyperplasia (good disease control) | Phase 2b | Trial Discontinued | Oral | Endocrinology |
